156 related articles for article (PubMed ID: 32060406)
1. Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease.
Mason MJ; Schinke C; Eng CLP; Towfic F; Gruber F; Dervan A; White BS; Pratapa A; Guan Y; Chen H; Cui Y; Li B; Yu T; Chaibub Neto E; Mavrommatis K; Ortiz M; Lyzogubov V; Bisht K; Dai HY; Schmitz F; Flynt E; Dan Rozelle ; Danziger SA; Ratushny A; ; Dalton WS; Goldschmidt H; Avet-Loiseau H; Samur M; Hayete B; Sonneveld P; Shain KH; Munshi N; Auclair D; Hose D; Morgan G; Trotter M; Bassett D; Goke J; Walker BA; Thakurta A; Guinney J
Leukemia; 2020 Jul; 34(7):1866-1874. PubMed ID: 32060406
[TBL] [Abstract][Full Text] [Related]
2. PHD finger protein 19 expression in multiple myeloma: Association with clinical features, induction therapy outcome, disease progression, and survival.
Li Y; Gong J; Zhang L
J Clin Lab Anal; 2021 Sep; 35(9):e23910. PubMed ID: 34390275
[TBL] [Abstract][Full Text] [Related]
3. Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a.
Yu T; Du C; Ma X; Sui W; Yu Z; Liu L; Zhao L; Li Z; Xu J; Wei X; Zhou W; Deng S; Zou D; An G; Tai YT; Tricot G; Anderson KC; Qiu L; Zhan F; Hao M
Mol Cancer Res; 2020 Jul; 18(7):1063-1073. PubMed ID: 32312841
[TBL] [Abstract][Full Text] [Related]
4. Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer.
Ghamlouch H; Boyle EM; Blaney P; Wang Y; Choi J; Williams L; Bauer M; Auclair D; Bruno B; Walker BA; Davies FE; Morgan GJ
J Exp Clin Cancer Res; 2021 Dec; 40(1):380. PubMed ID: 34857028
[TBL] [Abstract][Full Text] [Related]
5. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups.
Boyle EM; Rosenthal A; Ghamlouch H; Wang Y; Farmer P; Rutherford M; Ashby C; Bauer M; Johnson SK; Wardell CP; Wang Y; Hoering A; Schinke C; Thanendrarajan S; Zangari M; Barlogie B; Dhodapkar MV; Davies FE; Morgan GJ; van Rhee F; Walker BA
Leukemia; 2022 Feb; 36(2):591-595. PubMed ID: 34365473
[TBL] [Abstract][Full Text] [Related]
6. 1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma.
Johnson TS; Sudha P; Liu E; Becker N; Robertson S; Blaney P; Morgan G; Chopra VS; Dos Santos C; Nixon M; Huang K; Suvannasankha A; Zaid MA; Abonour R; Walker BA
Nat Commun; 2024 May; 15(1):4144. PubMed ID: 38755140
[TBL] [Abstract][Full Text] [Related]
7. PHF19 inhibition as a therapeutic target in multiple myeloma.
Schinke CD; Bird JT; Qu P; Yaccoby S; Lyzogubov VV; Shelton R; Ling W; Boyle EM; Deshpande S; Byrum SD; Washam C; Mackintosh S; Stephens O; Thanendrarajan S; Zangari M; Shaughnessy J; Zhan F; Barlogie B; van Rhee F; Walker BA
Curr Res Transl Med; 2021 Jul; 69(3):103290. PubMed ID: 33894670
[TBL] [Abstract][Full Text] [Related]
8. Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells.
Wen XY; Stewart AK; Sooknanan RR; Henderson G; Hawley TS; Reimold AM; Glimcher LH; Baumann H; Malek LT; Hawley RG
Int J Oncol; 1999 Jul; 15(1):173-8. PubMed ID: 10375612
[TBL] [Abstract][Full Text] [Related]
9. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
[TBL] [Abstract][Full Text] [Related]
10. EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation.
Adamik J; Jin S; Sun Q; Zhang P; Weiss KR; Anderson JL; Silbermann R; Roodman GD; Galson DL
Mol Cancer Res; 2017 Apr; 15(4):405-417. PubMed ID: 28119431
[TBL] [Abstract][Full Text] [Related]
11. Transcription factors Xbp-1, Blimp-1, and BSAP are involved in the regulation of plasmacytic differentiation induced by 2-methoxyestradiol in myeloma cell lines.
Jiang H; Gao W; Sze DM; Xiong H; Hou J
Int J Hematol; 2007 Dec; 86(5):429-37. PubMed ID: 18192112
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma.
Bi C; Chung TH; Huang G; Zhou J; Yan J; Ahmann GJ; Fonseca R; Chng WJ
Oncotarget; 2015 Sep; 6(28):26508-18. PubMed ID: 26164366
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic silencing of Aristaless-like homeobox-4, a potential tumor suppressor gene associated with lung cancer.
Liu WB; Han F; Du XH; Jiang X; Li YH; Liu Y; Chen HQ; Ao L; Cui ZH; Cao J; Liu JY
Int J Cancer; 2014 Mar; 134(6):1311-22. PubMed ID: 24037716
[TBL] [Abstract][Full Text] [Related]
14. The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
Stubbs MC; Burn TC; Sparks R; Maduskuie T; Diamond S; Rupar M; Wen X; Volgina A; Zolotarjova N; Waeltz P; Favata M; Jalluri R; Liu H; Liu XM; Li J; Collins R; Falahatpisheh N; Polam P; DiMatteo D; Feldman P; Dostalik V; Thekkat P; Gardiner C; He X; Li Y; Covington M; Wynn R; Ruggeri B; Yeleswaram S; Xue CB; Yao W; Combs AP; Huber R; Hollis G; Scherle P; Liu PCC
Clin Cancer Res; 2019 Jan; 25(1):300-311. PubMed ID: 30206163
[TBL] [Abstract][Full Text] [Related]
15. [Changes in gene expression profiles in multiple myeloma cells after knocking-down SNF5, a core subunit of SWI/SNF complex].
Xie Y; Xu Y
Nan Fang Yi Ke Da Xue Xue Bao; 2013 May; 33(5):667-71. PubMed ID: 23688984
[TBL] [Abstract][Full Text] [Related]
16. Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma.
Li S; Fu J; Lu C; Mapara MY; Raza S; Hengst U; Lentzsch S
Mol Cancer Ther; 2016 Apr; 15(4):711-9. PubMed ID: 26939700
[TBL] [Abstract][Full Text] [Related]
17. Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.
Sagawa M; Ohguchi H; Harada T; Samur MK; Tai YT; Munshi NC; Kizaki M; Hideshima T; Anderson KC
Clin Cancer Res; 2017 Sep; 23(17):5225-5237. PubMed ID: 28442502
[No Abstract] [Full Text] [Related]
18. Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors.
Moreaux J; Rème T; Leonard W; Veyrune JL; Requirand G; Goldschmidt H; Hose D; Klein B
Mol Cancer Ther; 2012 Dec; 11(12):2685-92. PubMed ID: 23087257
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.
Dupéré-Richer D; Licht JD
Curr Opin Hematol; 2017 Jul; 24(4):336-344. PubMed ID: 28441149
[TBL] [Abstract][Full Text] [Related]
20. Modulation of cereblon levels by anti-myeloma agents.
Díaz-Rodríguez E; Pandiella A
Leuk Lymphoma; 2016; 57(1):167-76. PubMed ID: 25860244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
